688443 智翔金泰
已收盘 01-13 15:00:00
资讯
新帖
简况
智翔金泰跌1.51% 连亏4年3季2023年上市募34.7亿
中金财经 · 01-12 18:18
智翔金泰跌1.51% 连亏4年3季2023年上市募34.7亿
每周股票复盘：智翔金泰（688443）GR1803注射液纳入优先审评
证券之星 · 01-11 04:30
每周股票复盘：智翔金泰（688443）GR1803注射液纳入优先审评
智翔金泰：GR1803注射液被纳入优先审评品种名单
证券之星 · 01-09
智翔金泰：GR1803注射液被纳入优先审评品种名单
1月9日智翔金泰涨11.17%，方正富邦鑫诚12个月持有混合A基金重仓该股
中金财经 · 01-09
1月9日智翔金泰涨11.17%，方正富邦鑫诚12个月持有混合A基金重仓该股
ORR高达89.5%！智翔金泰BCMA/CD3双抗申报上市
医药魔方 · 01-08
ORR高达89.5%！智翔金泰BCMA/CD3双抗申报上市
智翔金泰(688443.SH)：GR1803注射液附条件上市申请获得受理
智通财经 · 01-08
智翔金泰(688443.SH)：GR1803注射液附条件上市申请获得受理
每周股票复盘：智翔金泰（688443）变更2025年度签字注册会计师
证券之星 · 2025-12-28
每周股票复盘：智翔金泰（688443）变更2025年度签字注册会计师
智翔金泰跌1% 连亏4年3季2023年上市募34.7亿
中金财经 · 2025-12-08
智翔金泰跌1% 连亏4年3季2023年上市募34.7亿
智翔金泰(688443.SH)：赛立奇单抗注射液纳入2025年国家医保目录
智通财经 · 2025-12-07
智翔金泰(688443.SH)：赛立奇单抗注射液纳入2025年国家医保目录
每周股票复盘：智翔金泰（688443）取消监事会并召开业绩说明会
证券之星 · 2025-11-23
每周股票复盘：智翔金泰（688443）取消监事会并召开业绩说明会
智翔金泰（688443）披露取消监事会并修订公司章程公告，11月18日股价下跌1.46%
证券之星 · 2025-11-18
智翔金泰（688443）披露取消监事会并修订公司章程公告，11月18日股价下跌1.46%
每周股票复盘：智翔金泰（688443）拟取消监事会
证券之星 · 2025-11-16
每周股票复盘：智翔金泰（688443）拟取消监事会
智翔金泰（688443）披露拟取消监事会并修订公司章程，11月11日股价上涨0.1%
证券之星 · 2025-11-11
智翔金泰（688443）披露拟取消监事会并修订公司章程，11月11日股价上涨0.1%
智翔金泰跌1.25% 连亏4年3季2023年上市募34.7亿
中金财经 · 2025-11-06
智翔金泰跌1.25% 连亏4年3季2023年上市募34.7亿
股市必读：智翔金泰(688443)股东户数1.26万户，较上期增加7.75%
中金财经 · 2025-11-03
股市必读：智翔金泰(688443)股东户数1.26万户，较上期增加7.75%
每周股票复盘：智翔金泰（688443）Q3营收增1199.88%
证券之星 · 2025-11-02
每周股票复盘：智翔金泰（688443）Q3营收增1199.88%
智翔金泰（688443）披露2025年第三季度报告，10月30日股价上涨0.95%
证券之星 · 2025-10-30
智翔金泰（688443）披露2025年第三季度报告，10月30日股价上涨0.95%
图解智翔金泰三季报：第三季度单季净利润同比增长76.52%
证券之星 · 2025-10-30
图解智翔金泰三季报：第三季度单季净利润同比增长76.52%
一针难求？RSV来袭预防需求激增 企业加速抢占婴幼儿市场
滚动播报 · 2025-10-12
一针难求？RSV来袭预防需求激增 企业加速抢占婴幼儿市场
每周股票复盘：智翔金泰（688443）两款新药签署独家商业化协议
证券之星 · 2025-09-28
每周股票复盘：智翔金泰（688443）两款新药签署独家商业化协议
加载更多
公司概况
公司名称：
重庆智翔金泰生物制药股份有限公司
所属行业：
医药制造业
上市日期：
2023-06-20
主营业务：
重庆智翔金泰生物制药股份有限公司的主营业务是抗体药物的研发、生产与销售。公司的主要产品是抗体药物。
发行价格：
37.88
{"stockData":{"symbol":"688443","market":"SH","secType":"STK","nameCN":"智翔金泰","latestPrice":31.43,"timestamp":1768287600000,"preClose":31.95,"halted":0,"volume":5399296,"delay":0,"changeRate":-0.0163,"floatShares":117000000,"shares":367000000,"eps":-1.5914,"marketStatus":"已收盘","change":-0.52,"latestTime":"01-13 15:00:00","open":32.02,"high":32.49,"low":31.37,"amount":173000000,"amplitude":0.0351,"askPrice":31.44,"askSize":2,"bidPrice":31.43,"bidSize":12,"shortable":0,"etf":0,"ttmEps":-1.5914,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1768354200000},"marketStatusCode":5,"adr":0,"adjPreClose":31.95,"symbolType":"stock_kcb","openAndCloseTimeList":[[1768267800000,1768275000000],[1768280400000,1768287600000]],"highLimit":35.15,"lowLimit":28.76,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":366680000,"isCdr":false,"pbRate":6.45,"roa":"--","roe":"--","epsLYR":-2.17,"committee":-0.198915,"marketValue":11525000000,"turnoverRate":0.0463,"status":1,"afterMarket":{"amount":0,"volume":0,"close":31.43,"buyVolume":0,"sellVolume":0,"time":1768289637558,"indexStatus":"已收盘 01-13 15:30:00","preClose":31.95},"floatMarketCap":3667000000},"requestUrl":"/m/hq/s/688443","defaultTab":"news","newsList":[{"id":"2602151255","title":"智翔金泰跌1.51% 连亏4年3季2023年上市募34.7亿","url":"https://stock-news.laohu8.com/highlight/detail?id=2602151255","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602151255?lang=zh_cn&edition=full","pubTime":"2026-01-12 18:18","pubTimestamp":1768213083,"startTime":"0","endTime":"0","summary":"中国经济网北京1月12日讯 智翔金泰 今日收报31.95元，跌幅1.51%。 智翔金泰首次公开发行股票募集资金总额347,283.84万元；扣除发行费用后，募集资金净额为329,140.14万元。 智翔金泰已连亏4年3季。 2025年前三季度，智翔金泰实现营业收入2.08亿元，同比增长1,562.05%；实现归属于上市公司股东的净利润-3.33亿元；实现归属于上市公司股东的扣除非经常性损益的净利润-3.70亿元；经营活动产生的现金流量净额为-2.61亿元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushijujiao/20260112/31935008.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0239","688443"],"gpt_icon":0},{"id":"2602398945","title":"每周股票复盘：智翔金泰（688443）GR1803注射液纳入优先审评","url":"https://stock-news.laohu8.com/highlight/detail?id=2602398945","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602398945?lang=zh_cn&edition=full","pubTime":"2026-01-11 04:30","pubTimestamp":1768077025,"startTime":"0","endTime":"0","summary":"截至2026年1月9日收盘，智翔金泰报收于32.44元，较上周的27.24元上涨19.09%。自愿披露关于GR1803注射液纳入优先审评品种名单的公告重庆智翔金泰生物制药股份有限公司公告，其自主研发的GR1803注射液被国家药品监督管理局药品审评中心纳入优先审评品种名单。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011100001544.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688443","BK0239"],"gpt_icon":0},{"id":"2602321891","title":"智翔金泰：GR1803注射液被纳入优先审评品种名单","url":"https://stock-news.laohu8.com/highlight/detail?id=2602321891","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602321891?lang=zh_cn&edition=full","pubTime":"2026-01-09 17:36","pubTimestamp":1767951385,"startTime":"0","endTime":"0","summary":"智翔金泰(688443.SH)公告称，公司产品GR1803注射液被国家药品监督管理局药品审评中心纳入优先审评品种名单，拟定适应症为既往至少接受过三线治疗的复发或难治性多发性骨髓瘤成人患者。GR1803注射液是一款由公司自主研发的双特异性抗体药物，注册分类为治疗用生物制品1类。新药上市申请尚需经过多个环节，产品能否成功上市及上市时间存在不确定性。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010900028822.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688443","BK0239"],"gpt_icon":0},{"id":"2602233693","title":"1月9日智翔金泰涨11.17%，方正富邦鑫诚12个月持有混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2602233693","media":"中金财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602233693?lang=zh_cn&edition=full","pubTime":"2026-01-09 15:54","pubTimestamp":1767945245,"startTime":"0","endTime":"0","summary":"证券之星消息，1月9日智翔金泰涨11.17%创60日新高，收盘报32.44元，换手率9.94%，成交量11.59万手，成交额3.64亿元。根据2025基金Q3季报公募基金重仓股数据，重仓该股的公募基金共2家，其中持有数量最多的公募基金为方正富邦基金的方正富邦鑫诚12个月持有混合A。方正富邦鑫诚12个月持有混合A目前规模为0.24亿元，最新净值1.0641，较上一交易日上涨0.24%，近一年上涨12.05%。","market":"hk","thumbnail":" http://caiji.3g.cnfol.com/colect/202601/09/20260109744010.png","type":0,"news_type":0,"thumbnails":[" http://caiji.3g.cnfol.com/colect/202601/09/20260109744010.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushiyaowen/20260109/31929468.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["688443","BK0239"],"gpt_icon":0},{"id":"2601490365","title":"ORR高达89.5%！智翔金泰BCMA/CD3双抗申报上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2601490365","media":"医药魔方","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601490365?lang=zh_cn&edition=full","pubTime":"2026-01-08 19:01","pubTimestamp":1767870060,"startTime":"0","endTime":"0","summary":"1月8日，智翔金泰宣布双抗药物GR1803的附条件上市申请已获得国家药监局受理，用于治疗既往至少接受过三线治疗的复发或难治性多发性骨髓瘤成人患者。GR1803是智翔金泰自主研发的一款BCMA/CD3双抗药物，其结合BCMA的亲和力较结合CD3的亲和力高两个数量级。2025年11月，智翔金泰在ASH 2025年会上公布了GR1803治疗R/R MM的I期研究数据。结果显示，在至少接受了一次疗效评估的57例患者中，客观缓解率为89.5%。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-01-08/doc-inhfqyhi5239845.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["688443","BK0239","ORR"],"gpt_icon":0},{"id":"2601357820","title":"智翔金泰(688443.SH)：GR1803注射液附条件上市申请获得受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2601357820","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601357820?lang=zh_cn&edition=full","pubTime":"2026-01-08 17:35","pubTimestamp":1767864935,"startTime":"0","endTime":"0","summary":"智通财经APP讯，智翔金泰(688443.SH)发布公告，近日，公司收到了国家药品监督管理局下发的关于“GR1803注射液”境内生产药品注册上市许可申请的《受理通知书》，本次申请附条件批准上市的适应症为：本品适用于既往至少接受过三线治疗(包括一种蛋白酶体抑制剂、一种免疫调节剂和一种抗CD38单克隆抗体)的复发或难治性多发性骨髓瘤成人患者。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1390420.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"智翔金泰(688443.SH)：GR1803注射液附条件上市申请获得受理","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688443","BK0239"],"gpt_icon":0},{"id":"2594479632","title":"每周股票复盘：智翔金泰（688443）变更2025年度签字注册会计师","url":"https://stock-news.laohu8.com/highlight/detail?id=2594479632","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594479632?lang=zh_cn&edition=full","pubTime":"2025-12-28 05:03","pubTimestamp":1766869391,"startTime":"0","endTime":"0","summary":"截至2025年12月26日收盘，智翔金泰报收于26.91元，较上周的26.33元上涨2.2%。本周，智翔金泰12月25日盘中最高价报27.28元。公司公告汇总重庆智翔金泰生物制药股份有限公司于2025年12月24日发布公告，因原签字注册会计师徐伟东先生工作变动，不再担任公司2025年度审计项目签字会计师。本次变更为事务所内部工作调整，不影响公司年度审计工作的正常进行。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122800001345.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688443","BK0239"],"gpt_icon":0},{"id":"2589339345","title":"智翔金泰跌1% 连亏4年3季2023年上市募34.7亿","url":"https://stock-news.laohu8.com/highlight/detail?id=2589339345","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589339345?lang=zh_cn&edition=full","pubTime":"2025-12-08 17:47","pubTimestamp":1765187224,"startTime":"0","endTime":"0","summary":"中国经济网北京12月8日讯 智翔金泰 今日收报27.67元，跌幅1.00%。 智翔金泰首次公开发行股票募集资金总额347,283.84万元；扣除发行费用后，募集资金净额为329,140.14万元。 智翔金泰已连亏4年3季。 2025年前三季度，智翔金泰实现营业收入2.08亿元，同比增长1,562.05%；实现归属于上市公司股东的净利润-3.33亿元；实现归属于上市公司股东的扣除非经常性损益的净利润-3.70亿元；经营活动产生的现金流量净额为-2.61亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20251208/31850936.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["688443","BK0239"],"gpt_icon":0},{"id":"2589987957","title":"智翔金泰(688443.SH)：赛立奇单抗注射液纳入2025年国家医保目录","url":"https://stock-news.laohu8.com/highlight/detail?id=2589987957","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589987957?lang=zh_cn&edition=full","pubTime":"2025-12-07 16:18","pubTimestamp":1765095512,"startTime":"0","endTime":"0","summary":"智通财经APP讯，智翔金泰(688443.SH)发布公告，公司自主研发的赛立奇单抗注射液(金立希)成功纳入《国家基本医疗保险、生育保险和工伤保险药品目录》(以下简称“国家医保目录”)。新版国家医保目录将自2026年1月1日起正式实施。赛立奇单抗注射液是一款由公司自主研发的重组全人源抗IL-17A单克隆抗体，注册分类为治疗用生物制品Ⅰ类，作用靶点为IL-17A。该产品可特异性结合血清中的IL-17A蛋白，阻断IL-17A与IL-17RA的结合，抑制炎症的发生和发展，从而对IL-17A过表达的斑块状银屑病、放射学阳性中轴型脊柱关节炎等自身免疫性疾病达到治疗效果。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1378480.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","688443"],"gpt_icon":0},{"id":"2585105160","title":"每周股票复盘：智翔金泰（688443）取消监事会并召开业绩说明会","url":"https://stock-news.laohu8.com/highlight/detail?id=2585105160","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585105160?lang=zh_cn&edition=full","pubTime":"2025-11-23 03:48","pubTimestamp":1763840895,"startTime":"0","endTime":"0","summary":"截至2025年11月21日收盘，智翔金泰报收于26.79元，较上周的29.46元下跌9.06%。重庆智翔金泰生物制药股份有限公司将于2025年11月28日15:00-16:00通过网络互动方式在价值在线平台召开2025年第三季度业绩说明会，介绍公司经营业绩、发展战略等情况。重庆智翔金泰生物制药股份有限公司于2025年11月18日召开临时股东大会，审议通过取消监事会、修订公司章程等议案，董事会设职工代表董事一名。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112300000995.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688443"],"gpt_icon":0},{"id":"2584495597","title":"智翔金泰（688443）披露取消监事会并修订公司章程公告，11月18日股价下跌1.46%","url":"https://stock-news.laohu8.com/highlight/detail?id=2584495597","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584495597?lang=zh_cn&edition=full","pubTime":"2025-11-18 22:34","pubTimestamp":1763476465,"startTime":"0","endTime":"0","summary":"截至2025年11月18日收盘，智翔金泰报收于28.4元，较前一交易日下跌1.46%，最新总市值为104.14亿元。该股当日开盘28.7元，最高29.14元，最低28.23元，成交额达7141.33万元，换手率为2.14%。所有议案均获通过，其中取消监事会、修订公司章程为特别决议议案，已获有效表决权三分之二以上通过。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111800040105.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688443"],"gpt_icon":0},{"id":"2583651777","title":"每周股票复盘：智翔金泰（688443）拟取消监事会","url":"https://stock-news.laohu8.com/highlight/detail?id=2583651777","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583651777?lang=zh_cn&edition=full","pubTime":"2025-11-16 04:04","pubTimestamp":1763237057,"startTime":"0","endTime":"0","summary":"截至2025年11月14日收盘，智翔金泰报收于29.46元，较上周的28.99元上涨1.62%。本周，智翔金泰11月13日盘中最高价报30.05元。11月11日盘中最低价报28.7元。智翔金泰当前最新总市值108.02亿元，在生物制品板块市值排名30/51，在两市A股市值排名1774/5165。相关议案已提交董事会、监事会审议通过，尚需提交股东大会审议。公司将授权管理层办理工商变更登记及章程备案手续。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111600001102.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688443","BK0239"],"gpt_icon":0},{"id":"2582836034","title":"智翔金泰（688443）披露拟取消监事会并修订公司章程，11月11日股价上涨0.1%","url":"https://stock-news.laohu8.com/highlight/detail?id=2582836034","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582836034?lang=zh_cn&edition=full","pubTime":"2025-11-11 22:50","pubTimestamp":1762872632,"startTime":"0","endTime":"0","summary":"截至2025年11月11日收盘，智翔金泰报收于29.16元，较前一交易日上涨0.1%，最新总市值为106.92亿元。公司近日发布公告称，拟取消监事会，由董事会下设的审计委员会行使监事会职权，并相应修订《公司章程》及部分治理制度，包括《董事会议事规则》《股东会议事规则》《独立董事工作制度》等八项制度。相关议案已提交董事会、监事会审议通过，尚需提交股东大会审议。公司将授权管理层办理工商变更登记及章程备案手续。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111100041307.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688443","BK0239"],"gpt_icon":0},{"id":"2581905010","title":"智翔金泰跌1.25% 连亏4年3季2023年上市募34.7亿","url":"https://stock-news.laohu8.com/highlight/detail?id=2581905010","media":"中金财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581905010?lang=zh_cn&edition=full","pubTime":"2025-11-06 17:37","pubTimestamp":1762421826,"startTime":"0","endTime":"0","summary":"中国经济网北京11月6日讯 智翔金泰 今日收报29.23元，跌幅1.25%。 智翔金泰首次公开发行股票募集资金总额347,283.84万元；扣除发行费用后，募集资金净额为329,140.14万元。 智翔金泰已连亏4年3季。 2025年前三季度，智翔金泰实现营业收入2.08亿元，同比增长1,562.05%；实现归属于上市公司股东的净利润-3.33亿元；实现归属于上市公司股东的扣除非经常性损益的净利润-3.70亿元；经营活动产生的现金流量净额为-2.61亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20251106/31773547.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["688443","BK0239"],"gpt_icon":0},{"id":"2580237795","title":"股市必读：智翔金泰(688443)股东户数1.26万户，较上期增加7.75%","url":"https://stock-news.laohu8.com/highlight/detail?id=2580237795","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580237795?lang=zh_cn&edition=full","pubTime":"2025-11-03 08:04","pubTimestamp":1762128297,"startTime":"0","endTime":"0","summary":"来自交易信息汇总：10月31日主力资金净流入254.28万元，占总成交额1.25%。来自股本股东变化：截至2025年9月30日公司股东户数为1.26万户，较6月30日增加7.75%。来自业绩披露要点：2025年前三季度营业收入同比增长1,562.05%，但归属于上市公司股东的净利润为-332,592,518.58元。来自公司公告汇总：公司拟取消监事会，由董事会下设审计委员会行使监事会职权，相关议案将提交股东大会审议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushiyaowen/20251103/31760034.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["688443","BK0239"],"gpt_icon":0},{"id":"2580408376","title":"每周股票复盘：智翔金泰（688443）Q3营收增1199.88%","url":"https://stock-news.laohu8.com/highlight/detail?id=2580408376","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580408376?lang=zh_cn&edition=full","pubTime":"2025-11-02 08:46","pubTimestamp":1762044371,"startTime":"0","endTime":"0","summary":"截至2025年10月31日收盘，智翔金泰报收于30.32元，较上周的28.25元上涨7.33%。本周，智翔金泰10月28日盘中最高价报30.67元。本周关注点来自业绩披露要点：2025年第三季度营收同比增长1199.88%。股本股东变化截至2025年9月30日，智翔金泰股东户数为1.26万户，较6月30日增加909户，增幅7.75%。户均持股数量由3.13万股降至2.9万股，户均持股市值为88.62万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110200001923.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688443"],"gpt_icon":0},{"id":"2579259671","title":"智翔金泰（688443）披露2025年第三季度报告，10月30日股价上涨0.95%","url":"https://stock-news.laohu8.com/highlight/detail?id=2579259671","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579259671?lang=zh_cn&edition=full","pubTime":"2025-10-30 22:27","pubTimestamp":1761834474,"startTime":"0","endTime":"0","summary":"截至2025年10月30日收盘，智翔金泰报收于29.69元，较前一交易日上涨0.95%，最新总市值为108.87亿元。近日，智翔金泰发布2025年第三季度报告。公告显示，公司本报告期实现营业收入162,163,555.96元，较上年同期增长1,199.88%；年初至报告期末累计营业收入为207,555,345.29元，同比增长1,562.05%。研发投入方面，公司年初至报告期末研发投入合计为349,371,643.09元，同比下降20.22%；本报告期研发投入占营业收入的比例为80.18%。股东方面，截至报告期末，公司普通股股东总数为12,640户。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025103000045445.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688443","BK0239"],"gpt_icon":0},{"id":"2579425641","title":"图解智翔金泰三季报：第三季度单季净利润同比增长76.52%","url":"https://stock-news.laohu8.com/highlight/detail?id=2579425641","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579425641?lang=zh_cn&edition=full","pubTime":"2025-10-30 20:55","pubTimestamp":1761828932,"startTime":"0","endTime":"0","summary":"证券之星消息，智翔金泰2025年三季报显示，前三季度公司主营收入2.08亿元，同比上升1562.05%；归母净利润-3.33亿元，同比上升39.12%；扣非净利润-3.7亿元，同比上升32.78%；其中2025年第三季度，公司单季度主营收入1.62亿元，同比上升1199.88%；单季度归母净利润-4330.41万元，同比上升76.52%；单季度扣非净利润-5327.76万元，同比上升71.47%；负债率41.28%，投资收益579.57万元，财务费用-784.77万元，毛利率94.05%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025103000041784.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688443"],"gpt_icon":0},{"id":"2574461129","title":"一针难求？RSV来袭预防需求激增 企业加速抢占婴幼儿市场","url":"https://stock-news.laohu8.com/highlight/detail?id=2574461129","media":"滚动播报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2574461129?lang=zh_cn&edition=full","pubTime":"2025-10-12 00:25","pubTimestamp":1760199900,"startTime":"0","endTime":"0","summary":"据中国疾控中心10月9日发布的今年第40周全国急性呼吸道传染病哨点监测数据显示，RSV在哨点医院门急诊流感样病例、住院严重急性呼吸道感染病例的呼吸道样本检测阳性率中，均位列第二。 在RSV持续高发的背景下，其预防与治疗的市场想象空间不断被放大，一场聚焦该赛道的药物研发竞速赛正拉开帷幕，尽显百舸争流之态。 截至目前，全球尚无专门靶向RSV的特效药获批，现有干预以对症治疗为主。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2025-10-12/doc-inftpzyh5284825.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0239","LU2580892862.HKD","BK0070","01672","300142","LU2580892789.USD","02257","LU2148510915.USD","LU1064131003.USD","688276","300122","LU1328615791.USD","BK1161","688443","BK1515","LU1064130708.USD","159982","BK0046","BK0188","BK0077","06660","BK0196","BK1574"],"gpt_icon":0},{"id":"2570894459","title":"每周股票复盘：智翔金泰（688443）两款新药签署独家商业化协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2570894459","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2570894459?lang=zh_cn&edition=full","pubTime":"2025-09-28 03:54","pubTimestamp":1759002852,"startTime":"0","endTime":"0","summary":"截至2025年9月26日收盘，智翔金泰报收于31.6元，较上周的33.32元下跌5.16%。本周，智翔金泰9月23日盘中最高价报35.48元。本周关注点公司公告汇总：智翔金泰与康哲药业等就唯康度塔单抗和斯乐韦米单抗注射液签署独家商业化协议，获首付款1.1亿元。公司公告汇总重庆智翔金泰生物制药股份有限公司与西藏康哲药业发展有限公司、RXILIENT MEDICAL PTE. LTD.就唯康度塔单抗注射液和斯乐韦米单抗注射液分别签订独家合作协议。产品注册及商业化进程存在不确定性。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025092800000949.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688443"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1768293442986,"stockEarnings":[{"period":"1week","weight":0.1294},{"period":"1month","weight":0.1669},{"period":"3month","weight":0.1094},{"period":"6month","weight":0.0809},{"period":"1year","weight":0.3976},{"period":"ytd","weight":0.1729}],"compareEarnings":[{"period":"1week","weight":0.0353},{"period":"1month","weight":0.0709},{"period":"3month","weight":0.0776},{"period":"6month","weight":0.1888},{"period":"1year","weight":0.3146},{"period":"ytd","weight":0.0495}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"重庆智翔金泰生物制药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"12640人(较上一季度增加7.75%)","perCapita":"9231股","listingDate":"2023-06-20","address":"重庆市巴南区麻柳大道699号2号楼A区","registeredCapital":"36668万元","survey":" 重庆智翔金泰生物制药股份有限公司的主营业务是抗体药物的研发、生产与销售。公司的主要产品是抗体药物。","listedPrice":37.88},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"智翔金泰(688443)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供智翔金泰(688443)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"智翔金泰,688443,智翔金泰股票,智翔金泰股票老虎,智翔金泰股票老虎国际,智翔金泰行情,智翔金泰股票行情,智翔金泰股价,智翔金泰股市,智翔金泰股票价格,智翔金泰股票交易,智翔金泰股票购买,智翔金泰股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"智翔金泰(688443)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供智翔金泰(688443)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}